Persistence Market Research Company
Customize Now Get FREE Sample

Oral Biologics Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

Oral Biologics Market by Drug Class (Tumor Necrosis FactorAlpha Inhibitors, Lymphocyte Modulators, and Interleukin Inhibitors), by Indication (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease (IBD), Ulcerative Colitis, Cardiometabolic Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Analysis from 2026 to 2033.

ID: PMRREP32907| 199 Pages | 30 Dec 2025 | Format: PDF, Excel, PPT* | Healthcare

Market Growth and Regional Outlook Report by Persistence Market Research

Table of Content

  1. Executive Summary
    1. Global Oral Biologics Market Snapshot, 2026 and 2033
    2. Market Opportunity Assessment, 2026 – 2033, US$ Bn
    3. Key Market Trends
    4. Future Market Projections
    5. Premium Market Insights
    6. Industry Developments and Key Market Events
    7. PMR Analysis and Recommendations
  2. Market Overview
    1. Market Scope and Definition
    2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Key Trends
    3. Macro-Economic Factors
      1. Global Sectorial Outlook
      2. Global GDP Growth Outlook
    4. COVID-19 Impact Analysis
    5. Forecast Factors – Relevance and Impact
  3. Value Added Insights
    1. Product Adoption Analysis
    2. Recent Drug Class Launches
    3. Regulatory Landscape
    4. Value Chain Analysis
    5. Key Deals and Mergers
    6. PESTLE Analysis
    7. Porter’s Five Force Analysis
  4. Global Oral Biologics Market Outlook:
    1. Key Highlights
      1. Market Size (US$ Bn) and Y-o-Y Growth
      2. Absolute $ Opportunity
    2. Market Size (US$ Bn) Analysis and Forecast
      1. Historical Market Size (US$ Bn)  2020-2025
      2. Market Size (US$ Bn) Analysis and Forecast, 2026–2033
    3. Global Oral Biologics Market Outlook: Drug Class
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2020 – 2025
      3. Market Size (US$ Bn) Analysis  and Forecast, By Drug Class, 2026 – 2033
        1. Tumor Necrosis Factor-Alpha Inhibitors
        2. Lymphocyte Modulators
        3. Interleukin Inhibitors
      4. Market Attractiveness Analysis: Drug Class
    4. Global Oral Biologics Market Outlook: Indication
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn)  By Indication, 2020 – 2025
      3. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
        1. Rheumatoid Arthritis
        2. Psoriasis
        3. Inflammatory Bowel Disease (IBD)
        4. Ulcerative Colitis
        5. Cardiometabolic Disease
        6. Other
      4. Market Attractiveness Analysis: Indication
    5. Global Oral Biologics Market Outlook: Distribution Channel
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn)  By Distribution Channel, 2020 – 2025
      3. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
        1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. Market Attractiveness Analysis: Distribution Channel
  5. Global Oral Biologics Market Outlook: Region
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Region, 2020 – 2025
    3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2026 – 2033
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
    4. Market Attractiveness Analysis: Region
  6. North America Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. U.S.
      2. Canada
    4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    7. Market Attractiveness Analysis
  7. Europe Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Rest of Europe
    4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    7. Market Attractiveness Analysis
  8. East Asia Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. China
      2. Japan
      3. South Korea
    4. Market Size (US$ Bn) Analysis  and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    7. Market Attractiveness Analysis
  9. South Asia & Oceania Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. India
      2. Southeast Asia
      3. ANZ
      4. Rest of South Asia & Oceania
    4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    7. Market Attractiveness Analysis
  10. Latin America Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. Brazil
      2. Mexico
      3. Rest of Latin America
    4. Market Size (US$ Bn) Analysis  and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    7. Market Attractiveness Analysis
  11. Middle East & Africa Oral Biologics Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn)  By Market, 2020 – 2025
      1. By Country
      2. By Drug Class
      3. By Indication
      4. By Distribution Channel
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
      1. GCC Countries
      2. Egypt
      3. South Africa
      4. Northern Africa
      5. Rest of Middle East & Africa
    4. Market Size (US$ Bn) Analysis  and Forecast, By Drug Class, 2026 – 2033
      1. Tumor Necrosis Factor-Alpha Inhibitors
      2. Lymphocyte Modulators
      3. Interleukin Inhibitors
    5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
      1. Rheumatoid Arthritis
      2. Psoriasis
      3. Inflammatory Bowel Disease (IBD)
      4. Ulcerative Colitis
      5. Cardiometabolic Disease
      6. Other
    6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2026 – 2033
      1. Hospitals Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Others
    7. Market Attractiveness Analysis
  12. Competition Landscape
    1. Market Structure
      1. Competition Intensity Mapping By Market
      2. Competition Dashboard
    2. Company Profiles (Details – Overview, Recent Developments)
      1. Biocon Limited
        1. Overview
        2. Segments and Drug Class & Distribution Channel
        3. Key Financials
        4. Market Developments
        5. Market Strategy
      2. Pfizer Inc.
      3. AbbVie Inc.
      4. Lumen Bioscience Inc.
      5. Novo Nordisk A/S
      6. Eli Lilly and Company
      7. F. Hoffmann-La Roche Ltd 
      8. Oramed
      9. Johnson & Johnson
      10. Merck KGaA
      11. BeOne Medicines I GmbH
      12. EnteraBio Ltd.
      13. Rani Therapeutics
      14. BioMed X AG.
      15. Others
  13. Appendix
      1. Research Methodology
      2. Research Assumptions
      3. Acronyms and Abbreviations
We use cookies to improve user experience.
Google translate